Page last updated: 2024-10-27

fluconazole and Hematologic Malignancies

fluconazole has been researched along with Hematologic Malignancies in 56 studies

Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.

Research Excerpts

ExcerptRelevanceReference
"5 mg/kg twice daily; N=248) with fluconazole oral solution or capsules (400 mg daily; N=246) in 494 patients with anticipated profound neutropenia (i."9.12An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. ( Andreesen, R; Bertz, H; Bodenstein, H; Boewer, C; Cornely, O; Dölken, G; Glasmacher, A; Hänel, M; Junghanss, C; Pasold, R; Ullmann, AJ; Wandt, H; Wedding, U; Wolf, HH, 2006)
"A 7-year retrospective analysis of candidemia in patients with hematologic malignancies demonstrated that ten patients, who received itraconazole and fluconazole during neutropenia, developed breakthrough fungemia caused by fluconazole-resistant Candida albicans (C."7.73Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies. ( Kyo, T; Mikami, Y; Murayama, SY; Myoken, Y; Sugata, T, 2006)
" krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen."5.31Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. ( Henslee-Downey, JP; Mehta, J; Safdar, A; Singhal, S; van Rhee, F, 2001)
"5 mg/kg twice daily; N=248) with fluconazole oral solution or capsules (400 mg daily; N=246) in 494 patients with anticipated profound neutropenia (i."5.12An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. ( Andreesen, R; Bertz, H; Bodenstein, H; Boewer, C; Cornely, O; Dölken, G; Glasmacher, A; Hänel, M; Junghanss, C; Pasold, R; Ullmann, AJ; Wandt, H; Wedding, U; Wolf, HH, 2006)
"A 7-year retrospective analysis of candidemia in patients with hematologic malignancies demonstrated that ten patients, who received itraconazole and fluconazole during neutropenia, developed breakthrough fungemia caused by fluconazole-resistant Candida albicans (C."3.73Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies. ( Kyo, T; Mikami, Y; Murayama, SY; Myoken, Y; Sugata, T, 2006)
"Candida krusei is inherently resistant to fluconazole and is emerging as a frequent cause of fungemia in patients with hematologic malignant neoplasms."3.70Candida krusei fungemia. An escalating serious infection in immunocompromised patients. ( Abbas, J; Abi-Said, D; Bodey, GP; Girgawy, E; Hachem, R; Hanna, HA; Mardani, M; Raad, I; Whimbey, E, 2000)
"0 L and the bioavailability (F) was 81."2.90Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. ( Ding, XL; Liu, LN; Miao, LY; Tian, JX; Xue, L; Yan, HH; Zhang, JJ; Zhang, WJ; Zhang, WW, 2019)
"Micafungin treatment did not result in increasing adverse effects and had a safe profile as fluconazole in neutropenic patients."2.73Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. ( Asakura, S; Fujii, N; Hara, M; Hiramatsu, Y; Ikeda, K; Maeda, Y; Matsuo, K; Matsuoka, KI; Miyata, A; Nawa, Y; Saito, T; Shinagawa, K; Sunami, K; Tabayashi, T; Tanimoto, M; Yano, T, 2008)
"If fluconazole was administered orally, blood samples were drawn 2, 8, and 24 hr after ingestion of the drug."2.70Serum levels of fluconazole in patients after cytotoxic chemotherapy for hematological malignancy. ( Chiba, S; Hirai, H; Hirate, J; Kami, M; Kanda, Y; Kojima, N; Mori, S; Moriya, A; Saito, T; Sawada, Y; Yuji, K, 2001)
"In neutropenic patients with hematologic malignancies, prophylaxis with fluconazole significantly decreased fungal isolation and other indicators of fungal infection when compared with amphotericin B."2.69Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy. ( Fujimori, Y; Kakishita, E; Kanamaru, A; Okada, M; Okamoto, T; Takatsuka, H; Takemoto, Y; Tamura, S; Wada, H, 1999)
" Itraconazole has a broader spectrum of activity but the capsules give erratic bioavailability in neutropenic patients."2.69A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. ( Morgenstern, GR; Prentice, AG; Prentice, HG; Ropner, JE; Schey, SA; Warnock, DW, 1999)
"Fluconazole was discontinued when a neutrophil count above 1."2.69Antifungal prophylaxis with low doses fluconazole in patients with hematological malignancies. ( Goranov, S; Grudeva-Popova, J; Spasov, E; Vakrilov, V, 1999)
"Fluconazole prophylaxis was given to 12 patients for a mean of 21."2.69Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. ( Huijgens, PC; Simoons-Smit, AM; Timmers, GJ; Touw, D; van Loenen, AC; Zweegman, S, 2000)
"The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has changed over the last few decades, partially due to the increased use of antifungal agents to prevent IFIs."2.66Breakthrough invasive fungal infections: Who is at risk? ( Chen, SC; Cornely, OA; Hoenigl, M; Jenks, JD; Thompson, GR, 2020)
"Invasive fungal diseases (IFD) are associated with considerable morbidity and mortality in patients with hematological malignancies."2.55[Current Status and Future Perspectives of Primary Antifungal Prophylaxis in Patients with Hematological Malignancies-Review]. ( Li, Y; Yu, L, 2017)
"The fungal esophagitis in patients with hematologic malignancies was not rare."1.43[A clinical study of fungal esophagitis in 13 patients with hematologic malignancies]. ( Ai, H; Li, YF; Liu, YY; Mi, RH; Song, YP; Wei, XD; Zhang, LN; Zhou, YL, 2016)
"Dose reductions of 50-75% for both sirolimus and tacrolimus, in combination with standard dosing of azole antifungal agents, were necessary to achieve therapeutic drug concentrations for immunosuppressants and potentially avoid toxicities."1.42Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation. ( Fung, HC; Peksa, GD; Schultz, K, 2015)
"Most subjects (62%) had hematologic malignancies."1.39Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study. ( Lloyd, L; Meibohm, A; Schuster, MG; Strom, B, 2013)
"Patients with oral mucositis assessment scale scores <20 had higher colonization rates than those with higher scores."1.39Microbiology and epidemiology of oral yeast colonization in hemopoietic progenitor cell transplant recipients. ( Freytes, CO; Kirkpatrick, WR; Patterson, TF; Redding, SW; Toro, JJ; Westbrook, SD; Wiederhold, NP, 2013)
"Oral cheek mucosal specimens from 52 cancer patients receiving chemotherapy were cultured on CHROMagar Candida plates for Candida identification."1.35Fluconazole susceptibility and genotypic heterogeneity of oral Candida albicans colonies from the patients with cancer receiving chemotherapy in China. ( Lafleur, MD; Qi, C; Qi, QG; Sun, J, 2009)
"Fluconazole was given to 17 paitents, intraconazole was given to 21 patients, and intraconazole to the other 9 patients after they had no effect with fluconazole."1.35[Clinical features and treatment of invasive fungal infection in 47 patients with hematological malignancies]. ( Chen, SP; Shu, YG; Xu, YJ; Zhu, Y, 2008)
"Neutropenia was the leading risk factor for all candidemia, whereas the catheter was the leading risk factor for C."1.35The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. ( Hachem, R; Hanna, H; Jiang, Y; Kontoyiannis, D; Raad, I, 2008)
"Mucormycoses were diagnosed in six patients, (median age of 52 years; range, 26-74) treated between 2001-2004."1.33Mucormycoses in patients with hematologic malignancies: an emerging fungal infection. ( Bethge, WA; Einsele, H; Hebart, H; Horger, M; Kanz, L; Kröber, SM; Schmalzing, M; Schumacher, U; Stuhler, G, 2005)
"Cryptococcosis in patients with hematologic malignancies is a rare complication."1.32Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. ( Caira, M; Caramatti, C; Cinieri, S; D'Antonio, D; Del Favero, A; Fianchi, L; Girmenia, C; Martino, B; Martino, P; Masini, L; Melillo, L; Pagano, L; Todeschini, G, 2004)
"Fluconazole was effective as a single agent in 3 patients with solid tumors."1.31Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. ( Hachem, R; Minari, A; Raad, I, 2001)
" krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen."1.31Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. ( Henslee-Downey, JP; Mehta, J; Safdar, A; Singhal, S; van Rhee, F, 2001)

Research

Studies (56)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (10.71)18.2507
2000's34 (60.71)29.6817
2010's14 (25.00)24.3611
2020's2 (3.57)2.80

Authors

AuthorsStudies
Garcia-Effron, G1
Kontoyiannis, DP1
Lewis, RE1
Perlin, DS1
Xue, L1
Zhang, WJ1
Tian, JX1
Liu, LN1
Yan, HH1
Zhang, WW1
Ding, XL1
Zhang, JJ1
Miao, LY1
Kanda, Y3
Kimura, SI1
Iino, M1
Fukuda, T1
Sakaida, E1
Oyake, T1
Yamaguchi, H1
Fujiwara, SI1
Jo, Y1
Okamoto, A1
Fujita, H1
Takamatsu, Y1
Saburi, Y1
Matsumura, I1
Yamanouchi, J1
Shiratori, S1
Gotoh, M1
Nakamura, S1
Tamura, K1
Jenks, JD1
Cornely, OA1
Chen, SC1
Thompson, GR1
Hoenigl, M1
Li, Y1
Yu, L1
Tang, L1
Yang, XF1
Qiao, M1
Zhang, L1
Tang, XW1
Qiu, HY1
Wu, DP1
Sun, AN1
Kung, HC1
Johnson, MD1
Drew, RH1
Saha-Chaudhuri, P1
Perfect, JR1
Peksa, GD1
Schultz, K1
Fung, HC1
Vuichard, D1
Weisser, M1
Orasch, C1
Frei, R1
Heim, D1
Passweg, JR1
Widmer, AF1
Zhou, YL1
Wei, XD1
Mi, RH1
Ai, H1
Zhang, LN1
Liu, YY1
Li, YF1
Song, YP1
Hiramatsu, Y1
Maeda, Y1
Fujii, N1
Saito, T2
Nawa, Y1
Hara, M1
Yano, T1
Asakura, S1
Sunami, K1
Tabayashi, T1
Miyata, A1
Matsuoka, KI1
Shinagawa, K1
Ikeda, K1
Matsuo, K1
Tanimoto, M1
Nawrot, U1
Nowicka, J1
Wlodarczyk, K1
Slobbe, L1
Waal, Lv1
Jongman, LR1
Lugtenburg, PJ1
Rijnders, BJ1
Wang, J1
Zhan, P1
Zhou, R1
Xu, J1
Shao, X1
Yang, Y1
Ouyang, J1
Sobrevilla Calvo, P1
Sun, J1
Qi, C1
Lafleur, MD1
Qi, QG1
Wingard, JR1
Carter, SL1
Walsh, TJ1
Kurtzberg, J1
Small, TN1
Baden, LR1
Gersten, ID1
Mendizabal, AM1
Leather, HL1
Confer, DL1
Maziarz, RT1
Stadtmauer, EA1
Bolaños-Meade, J1
Brown, J1
Dipersio, JF1
Boeckh, M1
Marr, KA1
Almyroudis, NG1
Segal, BH1
Schuster, MG1
Meibohm, A1
Lloyd, L1
Strom, B1
Zeuli, JD1
Wilson, JW1
Estes, LL1
Westbrook, SD1
Kirkpatrick, WR1
Wiederhold, NP1
Freytes, CO1
Toro, JJ1
Patterson, TF1
Redding, SW1
Pagano, L1
Fianchi, L1
Caramatti, C1
D'Antonio, D2
Melillo, L1
Caira, M1
Masini, L1
Todeschini, G1
Girmenia, C2
Martino, B1
Cinieri, S1
Martino, P2
Del Favero, A1
Di Bonaventura, G1
Spedicato, I1
Picciani, C1
Piccolomini, R1
Minenko, SV1
Zhukov, NV1
Chimishkian, KL1
Sokolova, EN1
Ptushkin, VV1
Kumar, CP1
Sundararajan, T1
Menon, T1
Venkatadesikalu, M1
Glasmacher, A4
Prentice, AG3
Vardakas, KZ1
Michalopoulos, A1
Falagas, ME1
Bethge, WA1
Schmalzing, M1
Stuhler, G1
Schumacher, U2
Kröber, SM1
Horger, M1
Einsele, H2
Kanz, L1
Hebart, H2
Cornely, O1
Ullmann, AJ1
Wedding, U1
Bodenstein, H1
Wandt, H1
Boewer, C1
Pasold, R1
Wolf, HH1
Hänel, M1
Dölken, G1
Junghanss, C1
Andreesen, R1
Bertz, H1
Shen, Q1
Song, XM1
Xu, XP1
Wang, JM1
Djulbegovic, B1
Myoken, Y1
Kyo, T1
Sugata, T1
Murayama, SY1
Mikami, Y1
Pazos, C1
Moragues, MD1
Quindós, G1
Pontón, J1
del Palacio, A1
de Vries, R1
Daenen, S1
Tolley, K1
Prentice, A1
Howells, S1
Christopherson, H1
de Jong-van den Berg, LT1
Postma, MJ1
Zhu, Y1
Chen, SP1
Shu, YG1
Xu, YJ1
Nomura, S1
Iishii, K1
Inami, N1
Kimura, E1
Urase, F1
Hachem, R3
Hanna, H1
Kontoyiannis, D1
Jiang, Y1
Raad, I3
Ellis, ME1
Spence, D1
Ernst, P1
Greer, W1
Nouwen, JL1
van Belkum, A1
de Marie, S1
Sluijs, J1
Wielenga, JJ1
Kluytmans, JA1
Verbrugh, HA1
Takatsuka, H1
Takemoto, Y1
Okamoto, T1
Fujimori, Y1
Tamura, S1
Wada, H1
Okada, M1
Kanamaru, A1
Kakishita, E1
Morgenstern, GR1
Prentice, HG2
Ropner, JE1
Schey, SA1
Warnock, DW1
Huijgens, PC2
Simoons-Smit, AM2
van Loenen, AC2
Prooy, E1
van Tinteren, H1
Ossenkoppele, GJ1
Jonkhoff, AR1
Löffler, J1
Hrastnik, C1
Daum, G1
Jarque, I1
Saavedra, S1
Martin, G1
Pemán, J1
Pérez Bellés, C1
Sanz, MA1
Goranov, S1
Spasov, E1
Grudeva-Popova, J1
Vakrilov, V1
Timmers, GJ1
Zweegman, S1
Touw, D1
Böhme, A1
Karthaus, M1
Hoelzer, D1
Salonen, JH1
Richardson, MD1
Gallacher, K1
Issakainen, J1
Helenius, H1
Lehtonen, OP1
Nikoskelainen, J1
Tuccinardi, C1
Santilli, S1
Mondello, F1
Monaco, M1
Cassone, A1
Abbas, J1
Bodey, GP1
Hanna, HA1
Mardani, M1
Girgawy, E1
Abi-Said, D1
Whimbey, E1
Trenschel, R1
Peceny, R1
Runde, V1
Elmaagacli, A1
Dermoumi, H1
Heintschel von Heinegg, E1
Müller, KD1
Schaefer, UW1
Beelen, DW1
Paterson, PJ1
McWhinney, PH1
Potter, M1
Kibbler, CC1
Minari, A1
Kami, M2
Sawada, Y1
Mori, S1
Hirate, J1
Kojima, N1
Moriya, A1
Yuji, K1
Chiba, S1
Hirai, H2
Safdar, A1
van Rhee, F1
Henslee-Downey, JP1
Singhal, S1
Mehta, J1
Machida, U1
Okuzumi, K1
Matsumura, T1
Mori Si, S1
Hori, A1
Kashima, T1
Takaue, Y1
Sakamaki, H1
Yoneyama, A1
Mutou, Y1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Double-blind Trial of Fluconazole Versus Voriconazole for the Prevention of Invasive Fungal Infections in Allogeneic Blood and Marrow Transplant Patients (BMT CTN #0101)[NCT00075803]Phase 3600 participants (Actual)Interventional2003-11-30Completed
Collection of Granulocytes by Apheresis of Healthy Donors Stimulated With Filgrastim (G-CSF) and Dexamethasone[NCT01553214]Phase 41,000 participants (Anticipated)Interventional2012-12-31Recruiting
A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis[NCT03112031]Phase 250 participants (Actual)Interventional2017-10-10Completed
ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.[NCT00386802]Phase 4115 participants (Anticipated)Interventional2006-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Failure to Engraft

(NCT00075803)
Timeframe: day 42

Interventionparticipants (Number)
Fluconazole11
Voriconazole9

Frequency of Invasive Fungal Infections (IFI)

Incidence of proven, probably, or presumptive IFI (NCT00075803)
Timeframe: 1 year

Interventionpercentage of patients (Number)
Fluconazole13.7
Voriconazole12.7

Frequency of Use of Amphotericin B or Caspofungin

(NCT00075803)
Timeframe: 1 year

Interventionpercentage of patients (Number)
Fluconazole30.2
Voriconazole24.1

Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplant

(NCT00075803)
Timeframe: 180 days

Interventionpercentage of patients (Number)
Fluconazole74.9
Voriconazole78.2

Duration of Use of Amphotericin B or Caspofungin

(NCT00075803)
Timeframe: 180 days

,
Interventiondays (Mean)
Number of days on study drugStart day of empiric antifungal therapyDays of empiric antifungal therapy
Fluconazole91167
Voriconazole96127

Freedom From Possible, Presumptive, Probable, or Proven Invasive Fungal Infection, Death, or Withdrawal of Study Drug Due to Toxicity, Intolerance, or an Empirical Trial of Amphotericin B or Caspofungin Greater Than 14 Consecutive Days

(NCT00075803)
Timeframe: 1 year

,
Interventionparticipants (Number)
IFI after relapse/progressionIFI before engraftmentIFI who had failure to engraftIFI after aGVHD (grades II-IV)IFI while on study drug (up to day 100)IFI after premature withdrawal of study drugIFI after start other prophylaxis (not study drug)IFI after empiric therapy
Fluconazole2122111911813
Voriconazole8811410161112

Overall Survival

(NCT00075803)
Timeframe: 100, 180, and 365 days

,
Interventionpercentage of patients (Number)
100 days180 days365 days
Fluconazole85.480.070.2
Voriconazole90.181.267.8

Percentage of Patients With Invasive Fungal Infection at 100, 180, and 365 Days

(NCT00075803)
Timeframe: 100, 180, and 365 days

,
Interventionpercentage of patients (Number)
100 days180 days365 days
Fluconazole9.511.213.7
Voriconazole5.67.312.7

Relapse Free Survival

(NCT00075803)
Timeframe: 100, 180, and 365 days

,
Interventionpercentage of patients (Number)
100 days180 days365 days
Fluconazole83.174.963.3
Voriconazole86.173.961.2

Time to and Severity of Acute and Chronic Graft vs Host Disease (GVHD)

(NCT00075803)
Timeframe: 100 and 365 days

,
Interventionparticipants (Number)
Acute GVHD grade II-IV at day 100Acute GVHD grade III-IV at day 100Chronic GVHD at 1 year
Fluconazole13242138
Voriconazole11627137

Utility of Galactomannan Assay in Diagnosis of Aspergillus and Response to Therapy

Although there were 82 Galactomannan (GM) positives, 4 were excluded due to piperacillin/tazobactam administration, without other documentation of IFI, and were deemed false positives. (NCT00075803)
Timeframe: 1 year

,
Interventionparticipants (Number)
GM+GM-
Fluconazole43252
Voriconazole35270

Reviews

9 reviews available for fluconazole and Hematologic Malignancies

ArticleYear
Breakthrough invasive fungal infections: Who is at risk?
    Mycoses, 2020, Volume: 63, Issue:10

    Topics: Adrenal Cortex Hormones; Antifungal Agents; Aspergillus; Candida; Central Venous Catheters; Echinoca

2020
[Current Status and Future Perspectives of Primary Antifungal Prophylaxis in Patients with Hematological Malignancies-Review].
    Zhongguo shi yan xue ye xue za zhi, 2017, Volume: 25, Issue:2

    Topics: Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole; Mycoses

2017
Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:4

    Topics: Antibiotic Prophylaxis; Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole;

2010
[Fungal infections in oncohematology: the role of prophylaxis].
    Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46 Suppl C

    Topics: Antifungal Agents; Antineoplastic Agents; Fever; Fluconazole; Hematologic Neoplasms; Humans; Mycoses

2010
Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
    Expert review of anti-infective therapy, 2010, Volume: 8, Issue:12

    Topics: Amphotericin B; Antifungal Agents; Azoles; Clinical Trials as Topic; Echinocandins; Fluconazole; Hem

2010
Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    The Journal of antimicrobial chemotherapy, 2005, Volume: 56 Suppl 1

    Topics: Amphotericin B; Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole; Mycoses

2005
Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
    British journal of haematology, 2005, Volume: 131, Issue:1

    Topics: Antifungal Agents; Chi-Square Distribution; Fluconazole; Hematologic Neoplasms; Hematopoietic Stem C

2005
In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy.
    British journal of haematology, 2006, Volume: 132, Issue:5

    Topics: Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole; Mycoses; Opportunistic

2006
Antifungal prophylaxis in neutropenic patients with hematologic malignancies.
    Antibiotics and chemotherapy, 2000, Volume: 50

    Topics: Antifungal Agents; Antineoplastic Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Fluconaz

2000

Trials

14 trials available for fluconazole and Hematologic Malignancies

ArticleYear
Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients.
    Pharmaceutical research, 2019, Dec-23, Volume: 37, Issue:1

    Topics: Adolescent; Adult; Aged; Body Weight; Child; Child, Preschool; Cyclosporine; Dose-Response Relations

2019
D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 03-10, Volume: 38, Issue:8

    Topics: Adult; Aged; Antifungal Agents; Febrile Neutropenia; Female; Fluconazole; Hematologic Neoplasms; Hem

2020
Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study.
    Cancer medicine, 2014, Volume: 3, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Fluconazole; Hematologic Neoplasms; Humans;

2014
Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation.
    International journal of hematology, 2008, Volume: 88, Issue:5

    Topics: Adolescent; Adult; Aged; Antifungal Agents; Echinocandins; Female; Fluconazole; Hematologic Neoplasm

2008
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
    Blood, 2010, Dec-09, Volume: 116, Issue:24

    Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur

2010
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
    Blood, 2010, Dec-09, Volume: 116, Issue:24

    Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur

2010
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
    Blood, 2010, Dec-09, Volume: 116, Issue:24

    Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur

2010
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
    Blood, 2010, Dec-09, Volume: 116, Issue:24

    Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur

2010
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
    The Journal of antimicrobial chemotherapy, 2006, Volume: 57, Issue:2

    Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Double-Blind Method; Endpoint Determinati

2006
Diagnostic potential of (1,3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients.
    Revista iberoamericana de micologia, 2006, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Aged; Amphotericin B; Anemia, Aplastic; Antibodies, Fungal; Antibody Specificity;

2006
Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy.
    Drugs under experimental and clinical research, 1999, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Female; Fluconazole;

1999
A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.
    British journal of haematology, 1999, Volume: 105, Issue:4

    Topics: Adolescent; Adult; Aged; Antifungal Agents; Antineoplastic Agents, Phytogenic; Drug Interactions; Fe

1999
Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
    Journal of clinical pathology, 1999, Volume: 52, Issue:5

    Topics: Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Fluconazole; Hematologic Neoplasms; Hem

1999
Antifungal prophylaxis with low doses fluconazole in patients with hematological malignancies.
    Folia medica, 1999, Volume: 41, Issue:4

    Topics: Adult; Antifungal Agents; Female; Fluconazole; Hematologic Neoplasms; Humans; Male; Middle Aged; Myc

1999
Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial.
    Bone marrow transplantation, 2000, Volume: 25, Issue:8

    Topics: Adolescent; Adult; Aged; Amphotericin B; Bilirubin; Consumer Product Safety; Contraindications; Fema

2000
Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination.
    Bone marrow transplantation, 2000, Volume: 26, Issue:9

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis;

2000
Serum levels of fluconazole in patients after cytotoxic chemotherapy for hematological malignancy.
    American journal of hematology, 2001, Volume: 66, Issue:2

    Topics: Adult; Age Factors; Antifungal Agents; Antineoplastic Agents; Aspartate Aminotransferases; Dose-Resp

2001

Other Studies

33 other studies available for fluconazole and Hematologic Malignancies

ArticleYear
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:11

    Topics: Aged; Aged, 80 and over; Antifungal Agents; Candida tropicalis; Candidiasis; Caspofungin; Drug Resis

2008
Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study.
    Journal de mycologie medicale, 2018, Volume: 28, Issue:2

    Topics: Adolescent; Adult; Aged; Antifungal Agents; Child; China; Cost-Benefit Analysis; Female; Fluconazole

2018
Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015, Volume: 21, Issue:6

    Topics: Adult; Aged; Algorithms; Antifungal Agents; Azoles; Drug Dosage Calculations; Female; Fluconazole; H

2015
Weekly use of fluconazole as prophylaxis in haematological patients at risk for invasive candidiasis.
    BMC infectious diseases, 2014, Nov-11, Volume: 14

    Topics: Adult; Antifungal Agents; Candida; Candidemia; Candidiasis, Invasive; Drug Resistance, Fungal; Femal

2014
[A clinical study of fungal esophagitis in 13 patients with hematologic malignancies].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2016, Jun-14, Volume: 37, Issue:6

    Topics: Esophagitis; Fluconazole; Hematologic Neoplasms; Humans; Mycoses; Prognosis; Retrospective Studies;

2016
Susceptibility to voriconazole, fluconazole, and ketoconazole of yeast isolated from patients with hematological malignancies.
    Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:6

    Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Hematologic Neoplasms

2008
Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; An

2009
Fluconazole susceptibility and genotypic heterogeneity of oral Candida albicans colonies from the patients with cancer receiving chemotherapy in China.
    International journal of oral science, 2009, Volume: 1, Issue:3

    Topics: Adult; Aged; Antifungal Agents; Candida albicans; Candida glabrata; Candidiasis, Oral; China; DNA, F

2009
Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study.
    The Journal of infection, 2013, Volume: 66, Issue:3

    Topics: Adult; Aged; Antifungal Agents; Blood; Candida; Candidemia; Case-Control Studies; Culture Media; Dru

2013
Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:3

    Topics: Adult; Aged; Antifungal Agents; Drug Administration Schedule; Drug Therapy, Combination; Electrocard

2013
Microbiology and epidemiology of oral yeast colonization in hemopoietic progenitor cell transplant recipients.
    Oral surgery, oral medicine, oral pathology and oral radiology, 2013, Volume: 115, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Candida; Candida albicans; Candida glab

2013
Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection.
    Haematologica, 2004, Volume: 89, Issue:7

    Topics: Adolescent; Adult; Aged; Antifungal Agents; Cryptococcosis; Female; Fluconazole; Hematologic Neoplas

2004
In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:11

    Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Caspofungin; Colony Count, Microbial; Echin

2004
[Prophylaxis of fungal infection in patients with hematologic neoplasms and severe neutropenia after high-dose chemotherapy].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2004, Volume: 49, Issue:8-9

    Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Antineoplastic Agents; Fluconazole; Hema

2004
Candidosis in children with onco-hematological diseases in Chennai, south India.
    Japanese journal of infectious diseases, 2005, Volume: 58, Issue:4

    Topics: Antifungal Agents; Candida; Candidiasis; Child; Cohort Studies; Drug Resistance, Fungal; Female; Flu

2005
Mucormycoses in patients with hematologic malignancies: an emerging fungal infection.
    Haematologica, 2005, Volume: 90 Suppl

    Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Communicable Diseases, Emergi

2005
[Pulmonary fungal infection in malignant hematological diseases: an analysis of 14 cases].
    Zhongguo shi yan xue ye xue za zhi, 2005, Volume: 13, Issue:6

    Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Candidiasis; Female; Fluconazole; Hematol

2005
Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies.
    Haematologica, 2006, Volume: 91, Issue:2

    Topics: Candida albicans; Candidiasis; Drug Resistance; Fluconazole; Fungemia; Hematologic Neoplasms; Humans

2006
Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.
    PharmacoEconomics, 2008, Volume: 26, Issue:1

    Topics: Adolescent; Adult; Aged; Antifungal Agents; Antineoplastic Agents; Cost-Benefit Analysis; Female; Fl

2008
[Clinical features and treatment of invasive fungal infection in 47 patients with hematological malignancies].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2008, Volume: 33, Issue:1

    Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Candidiasis; Female; Fluconazole; Hematol

2008
Elevation of activated platelet-dependent chemokines and soluble cell adhesion molecules in patients with hematologic malignancies and high levels of beta-D-glucan.
    Pathophysiology of haemostasis and thrombosis, 2007, Volume: 36, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; b

2007
The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
    Cancer, 2008, Volume: 112, Issue:11

    Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Catheterization, Central Venous; Cohort Stu

2008
Variability of plasma fluconazole levels in patients with hematologic malignancy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1997, Volume: 24, Issue:1

    Topics: Alanine Transaminase; Antifungal Agents; Bilirubin; Candidiasis; Drug Interactions; Female; Fluconaz

1997
Clonal expansion of Staphylococcus epidermidis strains causing Hickman catheter-related infections in a hemato-oncologic department.
    Journal of clinical microbiology, 1998, Volume: 36, Issue:9

    Topics: Air Microbiology; Antibiotic Prophylaxis; Bacteriological Techniques; Catheterization, Central Venou

1998
Phospholipid and sterol analysis of plasma membranes of azole-resistant Candida albicans strains.
    FEMS microbiology letters, 2000, Apr-01, Volume: 185, Issue:1

    Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis; Cell Membra

2000
Delay of onset of candidemia and emergence of Candida krusei fungemia in hematologic patients receiving prophylactic fluconazole.
    Haematologica, 2000, Volume: 85, Issue:4

    Topics: Antifungal Agents; Candidiasis; Female; Fluconazole; Fungemia; Hematologic Neoplasms; Humans; Male;

2000
Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant Saccharomyces cerevisiae.
    The Journal of hospital infection, 2000, Volume: 45, Issue:4

    Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cross Infection;

2000
In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies.
    The Journal of antimicrobial chemotherapy, 2000, Volume: 46, Issue:3

    Topics: Antifungal Agents; Candida albicans; Candidiasis; Fluconazole; Hematologic Neoplasms; Humans; Microb

2000
Candida krusei fungemia. An escalating serious infection in immunocompromised patients.
    Archives of internal medicine, 2000, Sep-25, Volume: 160, Issue:17

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Antineoplastic Agents

2000
The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients.
    British journal of haematology, 2001, Volume: 112, Issue:1

    Topics: Amphotericin B; Antifungal Agents; Azoles; Bone Marrow Transplantation; Candida; Candidiasis; Drug R

2001
Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Jan-15, Volume: 32, Issue:2

    Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Bone Marrow Transplantation; Candida; Candidiasis; D

2001
Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
    Bone marrow transplantation, 2001, Volume: 28, Issue:9

    Topics: Adolescent; Adult; Antifungal Agents; Bacteremia; Bone Marrow Transplantation; Candida; Candidiasis;

2001
Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy.
    British journal of haematology, 2002, Volume: 117, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Aspergillosis; Autopsy; Candidiasis;

2002